Taken together, we have demonstrated that both pharmacological and surgical intervention regimens of T2D have the potential to influence IgA levels within the intestine, further supporting IgA as a regulator of glucose homeostasis. The gene discussed is CD79A; the disease is type 2 diabetes mellitus.